レーザー倒像検眼鏡の世界市場：2024年～2031年

レポート概要

レーザー倒像検眼鏡の世界市場は、2023年に1億1,529万米ドルに達し、2031年には1億6,049万米ドルに達すると予測され、予測期間2024年～2031年のCAGRは4.3%で成長すると予測されています。

レーザー倒像検眼鏡は、まぶしい露光と一過性の残像を生成するが、日常的な臨床使用において光化学的または熱的網膜障害を引き起こすという証拠はないです。麻酔をかけたアカゲザルに、網膜の1カ所に15分間照射すると局所的な光毒性傷害を引き起こす可能性があります。それでもなお、失明した眼や核出術を必要とするヒトのボランティアでは、即時的または長期的な網膜異常は検出されなかった。

市場力学：

促進要因と抑制要因

レーザー倒像検眼鏡の進歩の台頭

画質の向上、携帯性、使いやすさなど、レーザー倒像検眼鏡の技術的進歩も市場の成長に寄与しています。これらの進歩により、ヘルスケアプロバイダーにとってより身近で魅力的な機器となっています。デジタル画像や拡張現実などの技術は、レーザー倒像検眼鏡の機能を向上させ、より良い視覚化と眼疾患の診断を可能にしています。

例えば、Norlase社は、緑色レーザー光凝固装置とキーラー間接検眼鏡を組み合わせた新しいレーザー倒像検眼鏡（LIO）であるLIONを発表しました。このバッテリー駆動のLIOはファイバーテザーを必要とせず、パラメーターを音声でコントロールできる高度なワイヤレスインターフェースを採用しています。これにより、眼科医は事実上どこでも、縛られることなく、軽量で持ち運び可能なレーザー治療ソリューションを体験することができます。

規制上の課題

レーザー倒像検眼鏡は、市場で多くの規制上の課題に直面しています。これには、新機種に対するFDA認可の取得、規制機関が設定した安全性と性能の基準への適合、ラベル表示と文書化要件の遵守、国によって異なる規制の枠組みへの対応、より高度な機種の導入に伴う規制当局の監視強化への対応などが含まれます。これらの課題は、開発プロセスに時間とコストを追加し、レーザー倒像検眼鏡メーカーの世界な商品化努力を複雑にしています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • レーザー倒像検眼鏡の進歩の台頭
    • 眼疾患の有病率の上昇
  • 抑制要因
    • 規制上の課題
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 特許分析
• PESTLE分析
• SWOT分析
• DMIオピニオン

第6章 レーザータイプ別

• 光凝固レーザー
• 光破壊レーザー
• 光アブレーションレーザー

第7章 治療用途別

• 糖尿病網膜症
• 白内障
• 角膜混濁
• 緑内障
• 小児網膜修復
• 格子状変性症

第8章 エンドユーザー別

• 病院
• 眼科クリニック
• 外来手術センター（ASC）
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Iridex Corporation
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Meridian AG
• Lumenis
• Ellex Medical Lasers
• Carl Zeiss Meditec AG
• Nidek Co. Ltd.
• Ziemer Ophthalmic Systems AG
• Heine Optotechnik GmbH
• Keeler Ltd
• Topcon Medical Laser Systems Inc（*LIST NOT EXHAUSTIVE）

第12章 付録

Report Overview

The Global Laser Indirect Ophthalmoscope Market reached US$ 115.29 million in 2023 and is expected to reach US$ 160.49 million by 2031, growing at a CAGR of 4.3% during the forecast period 2024-2031.

Laser Indirect Ophthalmoscopes produce dazzling exposures and transient afterimages, but there is no evidence that they cause photochemical or thermal retinal injury in routine clinical use. A 15-minute exposure focused on a single retinal area can cause localized phototoxic injury in an anesthetized rhesus monkey. Still, no immediate or long-term retinal abnormalities could be detected in human volunteers with blind eyes or those requiring enucleation.

Market Dynamics: Drivers & Restraints

Rise of advancements in laser indirect ophthalmoscope

Technological advancements in laser indirect ophthalmoscopes, such as improved image quality, portability, and ease of use, are also contributing to the market's growth. These advancements make the devices more accessible and attractive to healthcare providers. Technologies like digital imaging and augmented reality are enhancing the capabilities of laser indirect ophthalmoscopes, allowing for better visualization and diagnosis of eye conditions.

For instance, Norlase has introduced the LION, a new laser indirect ophthalmoscope (LIO) that combines a green laser photocoagulator with a Keeler indirect ophthalmoscope. This battery-powered LIO requires no fiber tether and uses an advanced wireless interface with voice control of parameters. This allows ophthalmologists to experience an untethered, lightweight, and portable laser treatment solution virtually anywhere.

Regulatory challenges

The laser indirect ophthalmoscope faces numerous regulatory challenges in the market. These include obtaining FDA clearance for new models, meeting safety and performance standards set by regulatory bodies, adhering to labeling and documentation requirements, navigating differing regulatory frameworks across countries, and managing increased regulatory scrutiny as more advanced models are introduced. These challenges add time and costs to the development process and complicate global commercialization efforts for laser indirect ophthalmoscope makers.

Segment Analysis

The global laser indirect ophthalmoscope market is segmented based on laser type, therapeutic application, end-user, and region.

The photocoagulation laser from the laser type segment accounted for approximately 42.3% of the laser indirect ophthalmoscope market share

The photocoagulating laser from the laser type segment accounted for approximately 42.3%. Photocoagulation lasers, like argon and diode lasers, are widely used to treat retinal conditions like diabetic retinopathy and retinal vein occlusion by sealing blood vessels and reducing vision loss risk. This segment is expected to dominate due to increasing retinal disease incidence and photocoagulation therapy effectiveness.

For instance, in May 2023, Norlase, a leading global ophthalmic laser manufacturer developing next-generation laser solutions, announced it had received both FDA 510(k) clearance and CE Mark approval for the ECHO Green Pattern Laser photocoagulator.

Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like novel product launches, investment by key players, advanced healthcare infrastructure, high adoption of advanced medical technologies, and increasing healthcare expenditure. However, rapid economic development, growing healthcare investments,

For instance, in May 2023, Norlase, a leading laser technology company, secured its largest investment round to date, raising $11 million. The funding will enable Norlase to accelerate the production of its ECHO pattern laser, which has received FDA clearance and CE Mark. The investment will also advance Norlase's laser treatment solution portfolio. West Hill Capital led the round.

Competitive Landscape

The major global players in the market include Iridex Corporation, Meridian AG, Lumenis, Ellex Medical Lasers, Carl Zeiss Meditec AG, Nidek Co. Ltd., Ziemer Ophthalmic Systems AG, Heine Optotechnik GmbH, Keeler Ltd, Topcon Medical Laser Systems Inc among others.

Key Developments

In January 2021, Norlase announced that it had been granted the European CE Mark for the LION green laser system. LION combines the Keeler Vantage Plus diagnostic indirect with Norlase's groundbreaking compact laser technology into one device. With LION's untethered and portable design, physicians can move freely between treatment rooms - conveniently treating patients anywhere, anytime.

Why Purchase the Report?

To visualize the global laser indirect ophthalmoscope market segmentation based on laser type, therapeutic application, end user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

excel data sheet with numerous data points of the laser indirect ophthalmoscope market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as Excel consisting of key products of all the major players.

The global laser indirect ophthalmoscope market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Laser Type
• 3.2. Snippet by Therapeutic Application
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise of advancements in laser indirect ophthalmoscope
    • 4.1.1.2. Rise in the prevalence of eye disorders
  • 4.1.2. Restraints
    • 4.1.2.1. Regulatory challenges
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Patent Analysis
• 5.6. PESTLE Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Laser Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Laser Type
  • 6.1.2. Market Attractiveness Index, By Laser Type
• 6.2. Photocoagulation laser *
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Photo disrupting laser
• 6.4. Photo ablating laser

7. By Therapeutic Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
  • 7.1.2. Market Attractiveness Index, By Therapeutic Application
• 7.2. Diabetic retinopathy*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Cataract
• 7.4. Corneal opacities
• 7.5. Glaucoma
• 7.6. Pediatric retinal repairs
• 7.7. Lattice degeneration

8. By End User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 8.1.2. Market Attractiveness Index, By End User
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Ophthalmic Clinics
• 8.4. Ambulatory Surgery Centers (ASCs)
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Laser Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Laser Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. UK
    • 9.3.6.3. France
    • 9.3.6.4. Italy
    • 9.3.6.5. Spain
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Laser Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Laser Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Laser Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Iridex Corporation*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Meridian AG
• 11.3. Lumenis
• 11.4. Ellex Medical Lasers
• 11.5. Carl Zeiss Meditec AG
• 11.6. Nidek Co. Ltd.
• 11.7. Ziemer Ophthalmic Systems AG
• 11.8. Heine Optotechnik GmbH
• 11.9. Keeler Ltd
• 11.10. Topcon Medical Laser Systems Inc (*LIST NOT EXHAUSTIVE)

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us